Related references
Note: Only part of the references are listed.Involvement of WAVE Accumulation in Aβ/APP Pathology-Dependent Tangle Modification in Alzheimer's Disease
Kazuyuki Takata et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Regulation of platelet Rac1 and Cdc42 activation through interaction with calmodulin
Sherif M. Elsaraj et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2008)
IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1-42 by Rat Primary Type 2 Microglia
Eisuke Shimizu et al.
JOURNAL OF IMMUNOLOGY (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Amyloid-beta immunisation for Alzheimer's disease
Thomas Wisniewski et al.
LANCET NEUROLOGY (2008)
Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice
Joachim Hartmann et al.
NEUROCHEMISTRY INTERNATIONAL (2008)
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model
Takashi Yanagida et al.
NEUROSCIENCE RESEARCH (2008)
Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration
Kazuyuki Takata et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
The role of CaMKII as an F-actin-bundling protein crucial for maintenance of dendritic spine structure
Ken-Ichi Okamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients -: A biochemical analysis
R. Lyle Patton et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role
Tomohisa Suzuki et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice
C Unger et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cholinergic modulation of microglial activation by α7 nicotinic receptors
RD Shytle et al.
JOURNAL OF NEUROCHEMISTRY (2004)
The cognitive benefits of galantamine are sustained for at least 36 months - A long-term extension trial
MA Raskind et al.
ARCHIVES OF NEUROLOGY (2004)
Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo:: evidence for augmentation of a 42-specific γ secretase
JL Jankowsky et al.
HUMAN MOLECULAR GENETICS (2004)
Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity
T Kihara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
High mobility group box protein-1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity
K Takata et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors
M Samochocki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Androgens modulate beta-amyloid levels in male rat brain
M Ramsden et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw)
A Nordberg et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
Microglial activation and amyloid-β clearance induced by exogenous heat-shock proteins
J Kakimura et al.
FASEB JOURNAL (2002)
Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils
J Götz et al.
SCIENCE (2001)
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
J Lewis et al.
SCIENCE (2001)
Alzheimer's disease and related disorders
MA Raskind et al.
MEDICAL CLINICS OF NORTH AMERICA (2001)
α7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a β-amyloid-induced neurotoxicity
T Kihara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
A Maelicke et al.
BIOLOGICAL PSYCHIATRY (2001)
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
C Janus et al.
NATURE (2000)
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
D Morgan et al.
NATURE (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension
MA Raskind et al.
NEUROLOGY (2000)
Nicotinic receptor function: new perspectives from knockout mice
M Cordero-Erausquin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2000)
Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
A Maelicke et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
